NCT03672253Unknown1 期
Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年7月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Occurrence of treatment related adverse events
研究概览
简要总结
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a confirmed prior diagnosis of active multiple myeloma as defined by the updated IMWG criteria.
- •Patients with refractory multiple myeloma. Clear BCMA expression must be detected on malignant plasma cells from either bone marrow or a plasmacytoma by flow cytometry or immunohistochemistry.
- •Refractory disease：1) At least 3 prior regimens, which must at least have contained bortezomi. or 2) other circumstances identified by clinical doctors.
- •Relapse criteria in NCCN clinical practice guidelines in Oncology: Multiple Myeloma (2016.V2).
排除标准
- •Women of child-bearing potential or who are pregnant or breastfeeding.
- •Have any active and uncontrolled infection: hepatitis B, hepatitis C, HIV, or other fatal viral and bacterial infection.
- •Systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within 2 weeks prior to either the required leukapheresis or the initiation of the conditioning chemotherapy regimen.
- •Patients with any uncontrolled intercurrent illness or serious uncontrolled medical disorder.
- •Patients with CNS metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions and spinal cord compression).
- •History of allogeneic stem cell transplantation. Have active acute or chronic graft-versus-host-disease (GVHD), or require immunosuppressant medications for GVHD, within 6 months of enrollment.
- •Patients with active autoimmune skin diseases such as psoriasis or other active autoimmune diseases such as rheumatoid arthritis.
- •other conditions that excluded by clinicians.
研究组 & 干预措施
CAR-T Re-treatment group
Experimental
Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
干预措施: CAR-T Re-treatment (Drug)
结局指标
主要结局
Occurrence of treatment related adverse events
时间窗: Day 1-30 days after injection
assessed by CTCAE v4.0, \>= Grade 1 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment
次要结局
- Anti-myeloma responses(Day 1-60 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseNeoplasm, Plasma CellMultiple Myeloma in RelapseMultiple MyelomaNCT04776330Chongqing Precision Biotech Co., Ltd80
尚未招募
1 期
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple MyelomaMultiple MyelomaNCT06705725Carbiogene Therapeutics Co. Ltd.38
Unknown
2 期
B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple MyelomaMultiple MyelomaNCT03931421First Affiliated Hospital of Zhejiang University30
Unknown
2 期
Anti-BCMA CAR T-Cell Therapy for R/R ITPITPNCT05315778The First Affiliated Hospital of Soochow University5
Unknown
1 期
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma CellMultiple MyelomaNCT04272151Chongqing Precision Biotech Co., Ltd40